Tag: shockwave medical
Disrupt PAD III observational study results confirm safety and effectiveness of...
The final 1,373-patient cohort analysis from the Disrupt PAD III observational study (OS) demonstrates consistent intravascular lithotripsy (IVL; Shockwave Medical) outcomes in complex and...
Shockwave IVL: Maintaining options for patients with calcified PAD
Intravascular Lithotripsy (IVL; Shockwave Medical) gives physicians “the option to treat a patient efficiently without implanting something like a stent, which would limit further...
Shockwave IVL: Seeing is believing
Raphaël Coscas (Paris, France) talks to Vascular News about his introduction to Intravascular Lithotripsy (IVL; Shockwave Medical) and his initial experiences with the technology in...
Vascular News’ top 10 most popular stories of May 2022
Two-year data on the use of intravascular lithotripsy (IVL) in calcified peripheral disease treatment, an advertorial sponsored by Bentley exploring the role of bridging...
Shockwave Medical and Genesis MedTech obtain regulatory approval in China for...
Shockwave Medical and Genesis MedTech Group announced today that they have successfully obtained approval from China’s National Medical Products Administration (NMPA) to market and...
Shockwave IVL maintains superiority to angioplasty in calcified peripheral disease at...
Shockwave Medical announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with intravascular lithotripsy (IVL) led to...
Confined by the complexity of calcium? Expand the boundaries with Shockwave...
This educational supplement is only available in selected countries and geographies.
In this supplement, sponsored by Shockwave Medical:
Marianne Brodmann (Medical University of...
Shockwave Medical announces global launch of new peripheral IVL catheter
Shockwave Medical has announced the global commercial availability of the Shockwave M5+ peripheral intravascular lithotripsy (IVL) catheter after receiving both CE mark and US...
Vascular News’ top 10 most popular stories of November 2021
November's top 10 features a large-scale analysis of Philips' intravascular ultrasound (IVUS) in lower extremity peripheral vascular interventions, five-year data on Avenu Medical/Medtronic's Ellipsys...
Shockwave Medical enrols first patient in Disrupt BTK II study for...
Shockwave Medical has announced the start of the Disrupt BTK II postmarket study to assess the safety, effectiveness and optimal clinical use of the...
CMS increases hospital outpatient payment for peripheral intravascular lithotripsy
Shockwave Medical has announced that, as part of the calendar year 2022 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule, the Centers for...
VIVA 2021: IVL “consistently” treats real-world calcium in multiple peripheral vessel...
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL; Shockwave Medical) performs “consistently well” across challenging peripheral vessels,...
CMS creates new codes that establish specific payment for IVL performed...
Shockwave Medical has announced that as part of the calendar year 2021 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule, the Centers for...
The emerging value and broad applicability of intravascular lithotripsy
In this supplement, sponsored by Shockwave:
Frank Arko discusses his experience with intravascular lithotripsy (IVL) and considers its value in a resource-constrained healthcare environment
...
Shockwave Medical announces that CMS has created new codes for intravascular...
Shockwave Medical announced today that the Centers for Medicare & Medicaid Services (CMS) has issued new codes for intravascular lithotripsy (IVL) procedures performed in...
Shockwave IVL can aid in eliminating recoil and dissection during below-the-knee...
George Adams (Raleigh, USA) talks to VEITHtv at the VEITHsymposium 2019 (19–23 November, New York, USA) about the benefits of using easy-to-use Shockwave IVL (Intravascular Lithotripsy) in calcified...
IVL has “changed the dynamics” of facilitating EVAR & TEVAR in...
Frank Arko (Charlotte, USA) talks to VEITHtv at the VEITHsymposium 2019 (19–23 November, New York, USA), about the benefits of using Shockwave Intravascular Lithotripsy (IVL) when performing EVAR...
Shockwave announces commercial availability of below-the-knew IVL catheter
Shockwave Medical today announced commercial availability of the Shockwave S4 peripheral intravascular lithotripsy (IVL) catheter in select approved geographies. Shockwave S4 is a low-profile...
Intra-arterial calcification poses “one of the biggest challenges” for endovascular therapy
Andrew Holden (Auckland, New Zealand) provides perspective on the first results from the Disrupt PAD III observational registry that were presented at the Charing...
Abiomed invests $15 million in Shockwave Medical
A press release reports that Abiomed is to invest US$15 million in Shockwave Medical and the two companies will collaborate on a training and...
Consider intravascular lithotripsy when treating calcified femoropopliteal arteries
Treating severely calcified arteries by endovascular means is still a challenge, although atherectomy, stents and lithotripsy are all techniques that are employed. Lithotripsy (also...
Novel approach in treating stenotic peripheral arteries shown to be safe...
Twelve-month data prove that intravascular lithotripsy; a novel approach using pulsatile sonic pressure waves to modify intimal and medium calcium in stenotic peripheral arteries,...
“Fantastic” live case demonstrates potential value of intravascular lithotripsy
In an exciting session at the Charing Cross Symposium (CX; 24-27 April, London, UK), the audience witnessed the demonstration of a novel treatment strategy...
Shockwave Medical announces US$35 million in new financing
Shockwave Medical has reported US$35 million in new financing, an extension of the company’s previously announced US$45 million Series C financing. New investor Fidelity Management...
Shockwave Medical reports positive results for Lithoplasty in calcified lesions below...
Shockwave Medical has reported positive results from the DISRUPT BTK Study, which were presented at the annual Cardiovascular and Interventional Radiological Society of Europe...
Shockwave Medical Lithoplasty system launched in USA as first patient enrolled...
Shockwave Medical has announced two milestones for its Lithoplasty system for the treatment of calcified plaque in patients with peripheral artery disease (PAD): enrolment...
Shockwave Medical appoints Doug Godshall as president and chief executive officer
Shockwave Medical has announced the appointment of Doug Godshall as president and chief executive officer.
Godshall was most recently the chief executive officer and a...
First US patient treated in vascular study of Shockwave Medical Lithoplasty...
PinnacleHealth CardioVascular Institute has enrolled the first US patient in a trial assessing the safety and effectiveness of a new type of approach for...
Shockwave Medical raises US$45 Million in Series C financing to advance...
Shockwave Medical has announced the closing of US$45 million in Series C financing led by Sectoral Asset Management, with participation from mutual funds advised...
Shockwave Medical announces plans for “largest ever” calcified peripheral artery disease...
Shockwave Medical has announced plans for DISRUPT PAD III—what is claims is the “largest ever” multicentre randomised study to exclusively enrol patients with calcified...
Six-month Shockwave Medical Disrupt PAD data show “consistent and predictable” procedural...
Shockwave Medical has announced positive clinical results from the pooled DISRUPT PAD Study, a single-arm, two-phase, multicentre study evaluating the safety and performance of...
Shockwave Medical Lithoplasty system is cleared by the FDA
Shockwave Medica has announced clearance from the US Food and Drug Administration (FDA) of the Lithoplasty system for the treatment of calcified plaque in...
